Efficacy and safety analysis of a docetaxel-plus-trastuzumab regimen in patients with early-stage HER2-positive breast cancer: a retrospective single-arm study
The TH regimen demonstrated promise as a novel treatment alternative for patients with early-stage HER2-positive breast cancer. It offers a similar degree of efficacy and safety to those of the conventional WPH regimen while requiring fewer hospital visits, which could result in reduced healthcare costs and enhanced patient convenience.
Authors
- Toshinari Yamashita (ORCID: https://orcid.org/0000-0002-6479-1660)
- M. Chen (ORCID: https://orcid.org/0000-0003-0339-5215)
- Yang Liu (ORCID: https://orcid.org/0000-0002-9442-700X)
- Shusen Zheng (ORCID: https://orcid.org/0000-0003-1459-8261)
- Jia Yao (ORCID: https://orcid.org/0000-0001-9003-4279)
- Yaqun Zhang
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Zhejiang Library (CN)
- Blood Center of Zhejiang Province (CN)
- First Affiliated Hospital Zhejiang University (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Gland Surgery
- Published
- 2025-02-01
- DOI
- https://doi.org/10.21037/gs-2024-549
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00